January 11, 2022
Life Sciences
  • HHS Secretary Xavier Becerra ordered Medicare to “reassess” a proposed premium increase after Biogen’s Aduhelm fell in price. “Today I’m instructing the Centers for Medicare and Medicaid Services (CMS) to reassess the recommendation for the 2022 Medicare Part B premium, given the dramatic price change of the Alzheimer’s drug, Aduhelm,” Becerra said in a statement. “With the 50% price drop of Aduhelm on January 1, there is a compelling basis for CMS to reexamine the previous recommendation.” (Articles here, here, and here)